Prefilled Glass Syringe Formulation for Botulinum Toxin Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing botulinum toxin formulations are unstable, particularly at alkaline pH and heat-labile, leading to rapid loss of activity upon dilution, and current lyophilized products require reconstitution, which is inconvenient and prone to sterility issues, with limited shelf life and increased risk of contamination.
Innovation Solution
A prefilled glass container, such as a syringe, vial, or ampoule, containing an aqueous botulinum toxin formulation that maintains stability with minimal activity loss (less than 25%) for up to 24 months at various temperatures, ensuring high pH stability and low subvisible particle counts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If botulinum toxin is formulated as a dilute aqueous solution for injection, then it can be used directly without reconstitution, but the toxin activity is rapidly lost upon dilution and storage
Solution Approach 1:
The patent introduces specific stabilizing agents (excipients) as intermediaries between the botulinum toxin and the aqueous environment. These stabilizers mediate the interaction by protecting the toxin's three-dimensional structure from degradation while maintaining solubility and bioavailability, thus enabling direct injection without reconstitution while preserving toxin activity.
Solution Approach 2:
The patent optimizes multiple formulation parameters including pH (adjusted to specific ranges), ionic strength, temperature conditions, and concentrations of stabilizing agents. By carefully controlling these parameters, the formulation achieves a balance where the toxin remains stable in dilute aqueous solution without requiring reconstitution, thus improving ease of operation while maintaining reliability.
2Reliability
If lyophilized (freeze-dried) products are used, then toxin stability is improved, but reconstitution is required which is inconvenient and time-consuming
Solution Approach 1:
The patent applies preliminary action by pre-formulating the botulinum toxin in a stable aqueous solution containing optimized stabilizing agents before filling into the final container. This preliminary formulation step eliminates the need for subsequent reconstitution by the user, providing both stability and convenience simultaneously. The stabilizers are incorporated in advance to prevent degradation during storage and handling.
Solution Approach 2:
The patent changes the formulation parameters by using specific pH buffers, stabilizing agents, and concentration ranges that enable the toxin to remain stable in aqueous solution without requiring freeze-drying. This parameter optimization allows the product to be supplied as a ready-to-use liquid formulation, eliminating the reconstitution step while maintaining toxin stability.
3Ease of operation
If the toxin is stored at room temperature, then convenience is improved, but toxin activity deteriorates rapidly
Solution Approach 1:
The patent introduces thermal protection intermediaries in the form of stabilizing agents that shield the botulinum toxin from thermal degradation. These excipients act as mediators that maintain the toxin's structural integrity even at elevated temperatures, enabling room temperature storage while preserving toxin activity. The stabilizers interfere with heat-induced denaturation pathways.
Solution Approach 2:
The patent optimizes formulation parameters including the use of specific buffers, stabilizing agents at optimized concentrations, and pH adjustments that collectively enhance the toxin's thermal stability. These parameter changes raise the temperature threshold for degradation, allowing the product to be stored at room temperature without rapid loss of activity, thus improving storage convenience while maintaining reliability.
4Ease of operation
If prefilled syringes are used, then ease of administration is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent applies preliminary action by completing the formulation optimization and stability enhancement before the filling process. The botulinum toxin is pre-formulated with stabilizing agents and adjusted to optimal parameters in advance, which simplifies the subsequent prefilled syringe manufacturing process. This preliminary preparation reduces the complexity of sterilization and filling operations while maintaining product stability.
Solution Approach 2:
The patent optimizes formulation parameters such as viscosity, pH, and stabilizer concentrations to facilitate smooth filling into prefilled syringes. These parameter adjustments prevent foaming, air bubble formation, and clogging during the filling process, thereby reducing manufacturing complexity. The optimized formulation enables automated filling operations with higher efficiency and lower defect rates, offsetting the inherent complexity of prefilled syringe production.
Data Source
AI summary
The present invention relates to a prefilled glass container, such as a prefilled glass syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled container is stable at low to ambient temperature for a prolonged time period. Furthermore, the present invention relates to a kit comprising the botulinum toxin prefilled container, and to the use of the botulinum toxin prefilled container in therapeutic and cosmetic applications.